These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 36851864

  • 1. Mass spectrometry redefines optimal testosterone thresholds in prostate cancer patients undergoing androgen deprivation therapy.
    Beck J, Rouleau M, Lemire F, Neveu B, Déry M, Thériault B, Dubois G, Guérette D, Pouliot F.
    Prostate; 2023 May; 83(7):670-677. PubMed ID: 36851864
    [Abstract] [Full Text] [Related]

  • 2. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N, European Association of Urology.
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [Abstract] [Full Text] [Related]

  • 3. Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients.
    Wang Y, Dai B, Ye DW.
    Asian J Androl; 2017 Feb; 19(2):178-183. PubMed ID: 26975487
    [Abstract] [Full Text] [Related]

  • 4. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].
    Ji GJ, Huang C, Song G, Li XS, Song Y, Zhou LQ.
    Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug 18; 49(4):657-662. PubMed ID: 28816284
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment.
    Ku JY, Lee JZ, Ha HK.
    Korean J Urol; 2015 Oct 18; 56(10):689-94. PubMed ID: 26495069
    [Abstract] [Full Text] [Related]

  • 7. Impact of pre-treatment prostate tissue androgen content on the prediction of castration-resistant prostate cancer development in patients treated with primary androgen deprivation therapy.
    Shibata Y, Suzuki K, Arai S, Miyoshi Y, Umemoto S, Masumori N, Kamiya N, Ichikawa T, Kitagawa Y, Mizokami A, Sugimura Y, Nonomura N, Sakai H, Honma S, Kubota Y.
    Andrology; 2013 May 18; 1(3):505-11. PubMed ID: 23444052
    [Abstract] [Full Text] [Related]

  • 8. Rapidly decreasing level of prostate-specific antigen during initial androgen deprivation therapy is a risk factor for early progression to castration-resistant prostate cancer: A retrospective study.
    Ji G, Song G, Huang C, He S, Zhou L.
    Medicine (Baltimore); 2017 Sep 18; 96(36):e7823. PubMed ID: 28885333
    [Abstract] [Full Text] [Related]

  • 9. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
    Chung C, Abboud K.
    Am J Health Syst Pharm; 2022 Jul 22; 79(15):1224-1235. PubMed ID: 35390118
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy.
    de la Taille A, Martínez-Piñeiro L, Cabri P, Houchard A, Schalken J, Triptocare LT Study Group.
    BJU Int; 2017 Jan 22; 119(1):74-81. PubMed ID: 26919403
    [Abstract] [Full Text] [Related]

  • 15. Elevated IL-8, TNF-α, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival.
    Sharma J, Gray KP, Harshman LC, Evan C, Nakabayashi M, Fichorova R, Rider J, Mucci L, Kantoff PW, Sweeney CJ.
    Prostate; 2014 Jun 22; 74(8):820-8. PubMed ID: 24668612
    [Abstract] [Full Text] [Related]

  • 16. Resetting the Bar of Castration Resistance - Understanding Androgen Dynamics in Therapy Resistance and Treatment Choice in Prostate Cancer.
    Shore ND, Morgans AK, Ryan CJ.
    Clin Genitourin Cancer; 2021 Jun 22; 19(3):199-207. PubMed ID: 33129718
    [Abstract] [Full Text] [Related]

  • 17. Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question.
    Caramella I, Dalla Volta A, Bergamini M, Cosentini D, Valcamonico F, Berruti A.
    Endocrine; 2022 Dec 22; 78(3):441-445. PubMed ID: 35986139
    [Abstract] [Full Text] [Related]

  • 18. Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.
    Thelen P, Heinrich E, Bremmer F, Trojan L, Strauss A.
    Prostate; 2013 Nov 22; 73(15):1699-709. PubMed ID: 23868789
    [Abstract] [Full Text] [Related]

  • 19. Lower pretreatment serum testosterone level predicts poor prognosis in the patients with metastatic hormone-sensitive prostate cancer undergoing androgen deprivation therapy.
    Yoshida T, Kawai T, Hagiwara K, Yanagida K, Noda M, Tokura Y, Yoshimura I, Kaneko T, Nakagawa T.
    Jpn J Clin Oncol; 2024 Apr 06; 54(4):498-503. PubMed ID: 38251778
    [Abstract] [Full Text] [Related]

  • 20. Serum testosterone levels after medical or surgical androgen deprivation: a comprehensive review of the literature.
    Nishiyama T.
    Urol Oncol; 2014 Jan 06; 32(1):38.e17-28. PubMed ID: 23769268
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.